KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of Goods SoldCost Of Goods Sold By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome (Loss) Before Income Tax By RegionLong Lived Assets By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income (Loss) By SegmentOperating Income (Loss) By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant, And Equipment, NetRevenue By Category AvkareRevenue By Category Avkare AnnualRevenue By Category GenericsRevenue By Category Generics AnnualRevenue By Category SpecialtyRevenue By Category Specialty AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2025)

Amneal Pharmaceuticals has reported Gross Profit over the past 9 years, most recently at $297.2 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 13.05% year-over-year to $297.2 million; the TTM value through Dec 2025 reached $1.1 billion, up 9.1%, while the annual FY2025 figure was $1.1 billion, 9.1% up from the prior year.
  • Gross Profit for Q4 2025 was $297.2 million at Amneal Pharmaceuticals, up from $274.0 million in the prior quarter.
  • Over five years, Gross Profit peaked at $297.2 million in Q4 2025 and troughed at $166.4 million in Q4 2021.
  • A 5-year average of $225.4 million and a median of $217.7 million in 2022 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: skyrocketed 48.6% in 2021 and later decreased 11.87% in 2023.
  • Year by year, Gross Profit stood at $166.4 million in 2021, then rose by 29.44% to $215.4 million in 2022, then fell by 11.87% to $189.8 million in 2023, then surged by 38.48% to $262.9 million in 2024, then grew by 13.05% to $297.2 million in 2025.
  • Business Quant data shows Gross Profit for AMRX at $297.2 million in Q4 2025, $274.0 million in Q3 2025, and $286.3 million in Q2 2025.